Citations

Showing 10 of 108104 citations.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Gorelik, Mark , Chung, Sharon A. , Ardalan, Kaveh , Friedman, Kevin G. , Hayward, Kristen , Imundo, Lisa F., Lapidus, Sivia , Kim, Susan , Son, Mary Beth F. , Sule, Sangeeta , Mater, Heather Van, Yildirim‐Toruner, Cagri , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Rhee, Rennie L. , Stone, John H. , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Lapidus, Sivia K , Kim, Susan , Son, Mary Beth , Sule, Sangeeta , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Rhee, Rennie L , Stone, John H , Dua, Anisha B , Husainat, Nedaa M , Turner, Amy S , Mustafa, Reem A , Springer, Jason M , Kalot, Mohamad A , Binstadt, Bryce A. , Tremoulet, Adriana H. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B.

Mayo Clinic

Arthritis Care & Research | March 8, 2022 | Volume: 74 | Issue: 4 | Pages: 538-548

10.1002/acr.24838 | PMID 35257507 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Methods Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. Results We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease
Gorelik, Mark , Chung, Sharon A. , Ardalan, Kaveh , Friedman, Kevin G. , Hayward, Kristen , Imundo, Lisa F., Lapidus, Sivia , Kim, Susan , Son, Mary Beth F. , Sule, Sangeeta , Mater, Heather Van, Yildirim‐Toruner, Cagri , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Rhee, Rennie L. , Stone, John H. , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Lapidus, Sivia K , Kim, Susan , Son, Mary Beth , Sule, Sangeeta , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Rhee, Rennie L , Stone, John H , Dua, Anisha B , Husainat, Nedaa M , Turner, Amy S , Mustafa, Reem A , Springer, Jason M , Kalot, Mohamad A , Binstadt, Bryce A. , Tremoulet, Adriana H. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, James, Karen E.

Mayo Clinic

Arthritis & Rheumatology | March 8, 2022 | Volume: 74 | Issue: 4 | Pages: 586-596

10.1002/art.42041 | PMID 35257501 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Methods Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. Results We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.
Comment: Introducing the US Health Care System in 2035
Gross, Robert A., Jones, Lyell K , Gross, Robert A.

Mayo Clinic

Neurology | March 7, 2022 | Volume: 98 | Issue: 10 | Pages: 401-401

10.1212/wnl.0000000000200065 | PMID 35256523 Get It

US Health Care System in 2035
McClean, Jeffrey C., Avitzur, Orly, Jones, Lyell K , McClean, Jeffrey C., Avitzur, Orly

Mayo Clinic

Neurology | March 7, 2022 | Volume: 98 | Issue: 10 | Pages: 402-408

10.1212/wnl.0000000000200057 | PMID 35256518 Get It

The Role of in-person Focus Groups in the Management of Urinary Incontinence in Women From a Mixed-methods, Randomized Pilot Study.
Toma, Gina , Carolan, Alexandra , Buckner‐Petty, Skye , Vargas, Laura, Wolter, Christopher , Khan, Aqsa , Toma, Gina

Mayo Clinic

No container title available | March 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1382799/v1 Get It

Abstract Purpose: To assess the quantitative and qualitative components of in-person focus groups as a potential intervention for female patients with urinary incontinence.Methods: Women over the age of 18 seeking treatment for UI were randomized to standard care with focus group participation or to standard care alone. All participants completed validated questionnaires: MESA, UDI-6, OAB-SAT-q, PGI-S, PGI-I, SQoL-F, PHQ-9, IPAQ at the beginning and conclusion of the study. Questionnaires were analyzed with repeated measures of ANOVA models in an intention-to-treat manner. Three moderated focus group sessions were held and audio recorded. Recordings were transcribed and categorized by frequency into themes using grounded theory methodology. Results: A total of 10 control and 8 intervention participants agreed to participate. Seven women attended all three focus group sessions and were included in the final analysis. Transcripts from focus group sessions observed women identified most with (1) urinary incontinence (UI) as a chronic disease, (2) shame managing UI, and (3) social constraints of toileting. Participants self-reported appreciation of focus group participation and desire for on-going sessions. Analysis of the questionnaires did not demonstrate statistically significant differences.Conclusion: Data ascertained from questionnaires was unable to demonstrate a meaningful effect in improved treatment outcomes for control and intervention participants. Grounded theory analysis of transcripts identified four primary themes: (1) appreciation of the focus group, (2) UI as a gendered issue, (3) lack of public awareness, and (4) history of negative provider interactions. All focus group participants self-reported interest in attending future focus group sessions.
Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori
Shakir, Salika M. , Otiso, Joshua, Keller, George, Heule, Hillary Van, Osborn, Lucas J. , Cole, Nicolynn C., Schuetz, Audrey N. , Richter, Sandra S. , Couturier, Marc Roger , Cole, Nicolynn, Schuetz, Audrey N

Mayo Clinic

Microbiology Spectrum | March 7, 2022 | Volume: 10 | Issue: 2 | Pages: No page available

10.1128/spectrum.02111-21 | PMID 35254119 Get It

Routine antimicrobial susceptibility testing (AST) of Helicobacter pylori by agar dilution is difficult to perform and not practical in most clinical microbiology laboratories. The Etest gradient diffusion method can be a reliable alternative for H. pylori AST with the advantage of being a less laborious quantitative method. This work reveals that an optimized Etest method can provide acceptable performance for H. pylori AST and describes the challenges associated with this methodology.
Ultrasound‐guided percutaneous carpal tunnel release: A systematic review
Chou, Raymond , Robinson, David , Homer, Scott, Chou, Raymond C , Robinson, David M.

Mayo Clinic

PM&R | March 7, 2022 | Volume: 15 | Issue: 3 | Pages: 363-379

10.1002/pmrj.12801 | PMID 35254722 Get It

AbstractObjectiveCarpal tunnel syndrome (CTS) is the most common peripheral entrapment mononeuropathy. The purpose of this systematic review is to evaluate the reported clinical effectiveness and safety of ultrasound‐guided percutaneous carpal tunnel release (USCTR) for the treatment of CTS.Literature SurveyPubMed, EMBASE, and ScienceDirect databases were queried from database inception to February 20, 2021, to identify clinical studies on USCTR.MethodologyTwo reviewers independently completed title, abstract, and full‐text screening, and they extracted data in duplicate for analysis. Procedure techniques, outcome measures, and complications were descriptively analyzed.SynthesisEighty‐seven studies were eligible for screening. Twenty studies (three randomized controlled trials, three prospective cohort studies, and 14 case series) met inclusion criteria, with a total of 1772 USCTR cases. The overall level of evidence was very low, with seven studies with at least moderate risk of bias. Thirteen studies exceeded the minimal clinically important difference (MCID) for the Boston Carpal Tunnel Questionnaire Symptom Severity Scale (BCTQ‐SS) and Boston Carpal Tunnel Questionnaire Functional Status Scale (BCTQ‐FS), and six studies exceeded the MCID for the Quick Disabilities of Arm, Shoulder & Hand (QDASH). Five studies reported statistically significant improvement in these functional outcome measures as early as the first week post‐procedure. A major complication occurred in one patient who developed suspected compartment syndrome, and minor complications were reported in 24 patients.ConclusionsBased on very low level of evidence, early studies suggest that USCTR may be an effective treatment for CTS, with potential for short post‐procedure recovery times.
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
Khorrami, Mohammadhadi , Gad, Mohamed M. , Gupta, Amit , Patil, Pradnya D. , Viswanathan, Vidya Sankar , Rajiah, Prabhakar , Nock, Charles, Gilkey, Michael , Pennell, Nathan A , Madabhushi, Anant , Rajiah, Prabhakar , Madabhushi, Anant , Jazieh, Khalid , Saad, Anas M. , Fu, Pingfu , Madabhushi, Anant

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 7, 2022 | Volume: 10 | Issue: 3 | Pages: e003778

10.1136/jitc-2021-003778 | PMID 35256515 Get It

Background The landmark study of durvalumab as consolidation therapy in NSCLC patients (PACIFIC trial) demonstrated significantly longer progression-free survival (PFS) in patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) treated with durvalumab (immunotherapy, IO) therapy after chemoradiotherapy (CRT). In clinical practice in the USA, durvalumab continues to be used in patients across all levels of programmed cell death ligand-1 (PD-L1) expression. While immune therapies have shown promise in several cancers, some patients either do not respond to the therapy or have cancer recurrence after an initial response. It is not clear so far who will benefit of this therapy or what the mechanisms behind treatment failure are. Methods A total of 133 patients with unresectable stage III NSCLC who underwent durvalumab after CRT or CRT alone were included. Patients treated with durvalumab IO after CRT were randomly split into training (D1=59) and test (D2=59) sets and the remaining 15 patients treated with CRT alone were grouped in D3. Radiomic textural patterns from within and around the target nodules were extracted. A radiomic risk score (RRS) was built and was used to predict PFS and overall survival (OS). Patients were divided into high-risk and low-risk groups based on median RRS. Results RRS was found to be significantly associated with PFS in D1 (HR=2.67, 95% CI 1.85 to 4.13, p<0.05, C-index=0.78) and D2 (HR=2.56, 95% CI 1.63 to 4, p<0.05, C-index=0.73). Similarly, RRS was associated with OS in D1 (HR=1.89, 95% CI 1.3 to 2.75, p<0.05, C-index=0.67) and D2 (HR=2.14, 95% CI 1.28 to 3.6, p<0.05, C-index=0.69), respectively. RRS was found to be significantly associated with PFS in high PD-L1 (HR=3.01, 95% CI 1.41 to 6.45, p=0.0044) and low PD-L1 (HR=2.74, 95% CI 1.8 to 4.14, p=1.77e-06) groups. Moreover, RRS was not significantly associated with OS in the high PD-L1 group (HR=2.08, 95% CI 0.98 to 4.4, p=0.054) but was significantly associated with OS in the low PD-L1 group (HR=1.61, 95% CI 1.14 to 2.28, p=0.0062). In addition, RRS was significantly associated with PFS (HR=2.77, 95% CI 1.17 to 6.52, p=0.019, C-index=0.77) and OS (HR=2.62, 95% CI 1.25 to 5.51, p=0.01, C-index=0.77) in D3, respectively. Conclusions Tumor radiomics of pretreatment CT images from patients with stage III unresectable NSCLC were prognostic of PFS and OS to CRT followed by durvalumab IO and CRT alone.
Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer
Kanvinde, Shrey , Kulkarni, Tanmay A. , Deodhar, Suyash , Bhattacharya, Deep , Dasgupta, Aneesha

Mayo Clinic

BioTech | March 7, 2022 | Volume: 11 | Issue: 1 | Pages: 6

10.3390/biotech11010006 | PMID 35822814 Get It

The research and development of non-viral gene therapy has been extensive over the past decade and has received a big push thanks to the recent successful approval of non-viral nucleic acid therapy products. Despite these developments, nucleic acid therapy applications in cancer have been limited. One of the main causes of this has been the imbalance in development of delivery vectors as compared with sophisticated nucleic acid payloads, such as siRNA, mRNA, etc. This paper reviews non-viral vectors that can be used to deliver nucleic acids for cancer treatment. It discusses various types of vectors and highlights their current applications. Additionally, it discusses a perspective on the current regulatory landscape to facilitate the commercial translation of gene therapy.